Taking these challenges into account, testing the predictability of HER2 status in BC of either sex using DL-based techniques would require improved curation of datasets, large multi-centric cohorts, and multimodal approaches which takes both proteomic and genetic data into account. The gene discussed is ERBB2; the disease is breast cancer.